Meeting Overview - The third meeting of the board of directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd. was held on August 14, 2025, with all 7 directors present, complying with relevant regulations [1]. Agenda Items - The board approved the adjustment of the 2025 stock option incentive plan, reducing the number of incentive recipients from 45 to 43 and the total stock options from 9.1 million to 8.96 million due to the departure of 2 recipients [1][2]. - The board agreed to grant stock options to the 2025 incentive recipients, with the grant date set for August 14, 2025, and a total of 8.96 million stock options to be issued at an exercise price of 13.01 yuan per share [2][3]. - The board approved the use of self-owned funds and bank acceptance bills to finance fundraising projects, which will be replaced by the raised funds, enhancing fund efficiency and reducing costs [3][4].

证券代码：688488 证券简称：艾迪药业 公告编号：2025-043 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届监事会第五次 会议通知于 2025 年 8 月 11 日送达全体监事，会议于 2025 年 8 月 14 日在公司会 议室以现场结合通讯表决方式召开。本次会议由公司监事会主席庞秋晨先生召集 并主持，应到监事 3 人，实到监事 3 人。本次会议的召集和召开程序符合《中华 人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 与会监事就如下议案进行了审议，并表决通过以下事项： （一）审议通过《关于调整 2025 年股票期权激励计划相关事项的议案》 监事会认为：鉴于 2025 年股票期权激励计划首次授予的 2 名激励对象因离 《公司 2025 年股票期 江苏艾迪药业集团股份有限公司 性文件以及《公司章程》规定的任职资格，符合《上市公司股权激励管理办法》 等文件规 ...

Core Viewpoint - The company has approved the use of its own funds and bank acceptance bills to pay for fundraising projects, with plans to replace these with raised funds later, ensuring the normal implementation of fundraising projects [1][6][7] Summary of Fundraising Situation - The company raised a total of RMB 839.4 million by issuing 60 million shares at RMB 13.99 per share, with total issuance costs amounting to RMB 79.83 million [1][2] - The funds were fully received by July 13, 2020, and have been managed in a dedicated account as per regulatory requirements [1][2] Summary of Investment Projects - As of June 30, 2025, the raw material drug production R&D project has been completed, while other fundraising projects are ongoing [2][3] - Specific projects include the Phase III clinical project for Aibond (艾诺韦林片) and the ACC008 project, with total investments of RMB 53.22 million and RMB 38.60 million respectively [3][4] Reasons for Using Own Funds - The company has used its own funds and bank acceptance bills for several reasons, including the need to pay employee salaries and taxes, which cannot be paid directly from the fundraising account [4][5] - Additionally, payments for overseas equipment and services require foreign currency, which cannot be processed through the fundraising account [4][5] Operational Process for Fund Replacement - The company will regularly compile a detailed list of payments made with its own funds and bank acceptance bills, which will be approved by the financial department [5][6] - After approval, equivalent amounts will be transferred from the fundraising account to replace the funds used [5][6] Impact on Daily Operations - The use of own funds and bank acceptance bills is expected to enhance the efficiency of fund utilization without affecting the normal operation of fundraising projects or the company's daily business [6][7] Review Procedures - The board and supervisory committee have approved the proposal to use own funds and bank acceptance bills, which does not require shareholder approval [6][7] - The proposal aligns with regulatory requirements and does not alter the intended use of the raised funds [6][7]

Group 1 - The articles discuss the ongoing developments in land use and agricultural practices, highlighting the changes in acreage and the impact on production [1][2][3] - There is a focus on the regulatory environment affecting land use, with mentions of audits and assessments that continue to influence agricultural land management [2][4] - Projections for land use by 2025 indicate significant changes, with specific acreage targets set for various agricultural practices [1][3] Group 2 - The articles emphasize the importance of sustainable practices in agriculture, noting the need for compliance with environmental standards [2][4] - There are references to the economic implications of land use changes, including potential impacts on local economies and agricultural output [1][3] - The discussion includes the role of technology and innovation in improving agricultural efficiency and land management [2][3]

江苏艾迪药业集团股份有限公司 （6）中国证监会认定的其他情形。 律、法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》 《上市规则》等法律、法规和规范性文件规定的激励对象条件，符合公司《激 励计划（草案）》规定的激励对象条件。 监事会关于 2025 年股票期权激励计划 首次授予激励对象名单的核查意见（授予日） 励对象的情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； 江苏艾迪药业集团股份有限公司（以下简称"公司"） 监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-045 ? 股票期权首次授予日：2025 年 8 月 14 日 ? 股票期权首次授予数量：896.00 万份 ? 股票期权首次授予价格：13.01 元/份 ? 股权激励方式：股票期权 江苏艾迪药业集团股份有限公司《2025 年股票期权激励计划（草案）》（以 下简称"《激励计划（草案）》"或"本激励计划"）规定的公司 2025 年股票 期权激励计划首次授予条件已经成就，根据江苏艾迪药业集团股份有限公司（以 下简称"公司"或"本公司"）2025 年第二次临时股东会授权，公司于 2025 年 了《关于调整 2025 年股票期权激励计划相关事项的议案》《关于向 2025 年股票 期权激励对象首次授予股票期权的议案》，确定以 2025 年 8 月 14 日为首次授予 日，以人民币 13.01 元/份的价格向 43 名首次授予激励对象授予 896.00 万份股票 期权。现将有关事项说明如下： 一、2025 年股票期权激励计划权益授予情况 江苏艾迪药业集团股份有限公司 关于向 2025 年股票期权激励计划激励对象 首次授予股票期权的公告 本公司董事会及全体董事 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-044 江苏艾迪药业集团股份有限公司 关于调整 2025 年股票期权激励计划相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司《2025 年股票期权激励计划（草案）》（以 下简称"《激励计划（草案）》"或"本激励计划"）规定的公司 2025 年股票 期权激励计划首次授予条件已经成就，根据江苏艾迪药业集团股份有限公司（以 下简称"公司"或"艾迪药业"）2025 年第二次临时股东会授权，公司于 2025 年 8 月 14 日召开第三届董事会第五次会议和第三届监事会第五次会议，审议通 过了《关于调整 2025 年股票期权激励计划相关事项的议案》。现将有关事项说 明如下： 一、已履行的决策程序和信息披露情况 了《关于公司<2025 年股票期权激励计划（草案）>及其摘要的议案》《关于公 司<2025 年股票期权激励计划实施考核管理办法>的议案》《关于提请股东会授 权董事会办理公司 2025 年股票期权激励计划相关事宜的议案》，相 ...

Core Points - The company has conducted a review of the initial grant list for the 2025 stock option incentive plan, confirming that it aligns with the approved draft by the second extraordinary general meeting of shareholders in 2025 [1][2] - A total of 8.96 million stock options will be granted to 43 incentive recipients, with an exercise price set at 13.01 yuan per option, effective from August 14, 2025 [2] Summary by Categories Incentive Recipients - The list of incentive recipients is consistent with the conditions outlined in the company's 2025 stock option incentive plan draft [1][2] - The recipients meet the qualifications as per relevant laws, regulations, and the company's articles of association [2] Compliance and Regulations - The review confirms that none of the recipients fall under categories that would disqualify them from receiving stock options, such as being deemed inappropriate by the securities exchange or regulatory authorities within the last 12 months [1][2] - The review adheres to the stipulations set forth in the Company Law, Securities Law, and other regulatory frameworks [1][2]

江苏艾迪药业集团股份有限公司 董事、总裁、首席执行 （截至授予日） 官 公司 2025 年股票期权激励计划首次授予的股票期权在各激励对象间的分配 情况如下表： | | | | 获授的股票 | | 占首次授 | | 占本激励计划 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序 | | | | | | | | | | 姓名 | 国籍 | 职务 | | 期权数量 | | 予权益总 | | 公告时股本总 | | 号 | | | | | | | | | | | | | （万份） | | 数的比例 | | 额的比例 | | | 首次授予部分 | | | | | | | | | 授予数量作相应调整，可以将该激励对象放弃的权益份额直接调减或在其他激励对象之间进 行分配。 露前确定，经董事会提出、监事会发表明确意见、律师发表专业意见并出具法律意见书后， 公司在指定网站按要求及时准确披露当次激励对象相关信息。 江苏艾迪药业集团股份有限公司董事会 核心技术（业务）骨干人员（37 人） 436.00 48.661% 1.036% 首次授予合计 896.0 ...

Core Viewpoint - The company announced the approval of several proposals, including adjustments to the 2025 stock option incentive plan, during the fifth meeting of the third board of directors [2] Group 1 - The company held its fifth meeting of the third board of directors on August 14 [2] - The board approved the proposal regarding adjustments to the 2025 stock option incentive plan [2]